Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages 1-9

  Maticic, Mojca ^a   Videcnik Zorman, Jerneja ^a   Gregorcic, Sergeja ^a   Schatz, Eberhard ^b   Lazarus, Jeffrey V ^c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b Correlation Network Foundation De Regenbook Groep ^*  (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EUROPEAN; HEPATITIS C; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; STRATEGIC PLANNING; STRUCTURED QUESTIONNAIRE; TREATMENT PLANNING; ADULT; COMPLICATION; EUROPE; FEMALE; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE SURVEY; SUBSTANCE ABUSE; TRANSMISSION;

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL AGENTS; EUROPE; FEMALE; GOVERNMENT PROGRAMS; HEALTH CARE SURVEYS; HEALTH POLICY; HEPATITIS C; HUMANS; PRACTICE GUIDELINES AS TOPIC; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84908301739     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S6-S14     Document Type: Article

References (78)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008, 103:1283-1297.
3. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med Sci 2006, 3:47-52. 1415841, 16614742.
4. van Meer S, de Man RA, Siersema PD, Erpecum KJ. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013, 19:6744-6756. 3812474, 24187450.
5. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assesement of incidence, prevalence, morbidity and mortality. BMC Public Health 2009, 22:34-42.
6. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012, 26:531-548.
7. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29:74-81.
8. World Health Organization Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 2000, 75:18-19. World Health Organization.
9. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Petrle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiesing L. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011, 18(Suppl 1):1-16.
10. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48:148-162.
11. Degenhardt L, Hall L. Extent of illict drug use and dependence, and their contribution to the global burden of disease. Lancet 2012, 379:55-70.
12. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011, 203:587-594. 3072736, 21282191.
13. Wiessing L, Guarita B, Giraudon I, Brummer-Korvenkontio H, Salminen M, Cowan SA. European monitoring of notifications of hepatitis C in the general population and among injecting drug users - the need to improve quality and comparability. Eurosurveillance 2008, 13:1-5.
14. Hagan H, Snyder N, Hough E, Yu T, McKeirnan S, Boase J, Duchin J. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health 2002, 79:579-585. 3456717, 12468677.
15. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009, 49:561-573.
16. Dalgaard O. Follow up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005, 40:336-338.
17. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011, 54:1137-1144.
18. Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, Tyndall MF. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011, 18:32-41.
19. Darke S, Kaye S, Duflou J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction 2006, 101:1771-1777.
20. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M, Robertson C, Donaghy M, Hayes P, Graham L, Goldberg DJ. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009, 18:271-283.
21. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005, 42:63-71.
22. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998, 27:1730-1735.
23. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illict-drug users?. N Engl J Med 2001, 345:211-215. 1510901, 11463019.
24. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver International 2014, doi: 10.1111/liv.12565.
25. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ, . International Network on Hepatitis in Substance Users Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013, 57(Suppl 2):129-137. International Network on Hepatitis in Substance Users.
26. Gerkens S, Natasha M, Thiry N, Hulstaert F. KCE Reports 173B Type Health Technology Assesment (HTA). https://kce.fgov.be/fr/node/1370.
27. Husic-Selimovic A, Vukobrat-Bijedic Z, Bevanda M, Mesihovic R, Zerem E, Ahmetagic S, Trbojevic S, Verhaz A, Kezic Z, Zildzic M, Bojanic J, Petrovic J, Stojic V, Ferhatovic M, Ibrahimpasic N, Mrdjen V, Zivlak N, Barac T, Bebek-Ivankovic H, Calkic L, Karin M, Dobrovoljski A, Rajic R, Skrbic M, Babic N, Bevanda-Glibo D. Diagnosis and treatment of chronic viral hepatitis B and C: doctrinal approach. Med Arh 2012, 66(Suppl 1):56-68.
28. Annual report: The Czech Republic drug situation - 2011. , http://www.Drogy-info.cz/index.php/English/annual_reports_and_other_main_resources/annual_report_th_czech_republic_drug_situation_2011
29. Health promotion for young prisoners. , http://www.adiktologie.cz/en/articles/detail/414/4008/Health-promotion-for-young-prisoners-HPYP-
30. Štefunkova M. Mortality and health status of former injecting drug users using low-treshold services in 1994 - follow-up study. , http://www.adiktologie.cz/en/articles/detail/414/4007/Mortality-and-health-status-of-former-injecting-drug-users-using-low-threshold-services-in-1994-follow-up-study
31. National handlingsplan til forebyggelse af hepatitis C. , http://www.sst.dk/publ/Publ2007/CFF/Stofmisbrugere/Forebyggelse_hepC_stofmisbrugere.pdf
32. Vejledning om HIV og hepatitis B og V virus. , http://www.sst.dk/publ/Publ2013/03mar/HIVogHepBogCvejl.pdf
33. Ministry of social affairs. , http://www.sm.ee
34. National institute for health and welfare. , http://www.thl.fi
35. French National Authority of Health. , http://www.has-sante.fr
36. French Ministry of Social Affairs and Health. , http://www.sante.gouv.fr
37. Backmund M. Leitlinien der Deutschen Gesellschaftfür Suchtmedizin (DGS e.V.): Therapie der chronischen Hepatitis C beiintravenös Drogengebrauchern. Suchtmed 2006, 8:129-133., http://www.dgsuchtmedizin.de/uploads/media/Leitlinien_Hepatitis_C.pdf
38. Hepatitis-C_virus (HCV)-infektion; prophylaxe, diagnostic und therapie. , http://www.awmf.org/leitlinien/detail/ll/021-012.html
39. Hellenic center for disease control and prevention. , http://www.keelpno.gr
40. MEGHÍVÓ - Krónikus vírushepatitisek kivizsgálási és kezelési protokollja. , http://www.informed.hu/informed_site-ok/majbeteg/alapitvany/meghivo-kronikus-virushepatitisek-kivizsgalasi-es-kezelesi-protokollja-185078.html
41. Health service executive. National hepatitis C strategy 2011-2014. , http://www.hse.ie/eng/services/Publications/HealthProtection/HepCstrategy.pdf
42. Epatite C, a chepunto siamo?. , http://www.infermieri24.it/approfondimento/show/124/epatite-punto-siamo.html
43. Gruppodi lavoro epatiti. , http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3275&area=Malattie%20infettive&menu=vuoto
44. Viksna L, Rozentale B, Kuse V. MEGHÍVÓ - Krónikus vírushepatitisek kivizsgálási és kezelési protokollja. , http://www.vmnvd.gov.lv/uploads/files/4d08c09c5b481.pdf
45. Lietuvos Respublikos Sveikatos Apsaugos Ministras Isakymas. Del letinio virusinio C hepatitio diagnostikos ir ambulatorinio gydymo kompensuojamaisiais vaistais tvarkos apraso tvirtinimo. , http://www.vlk.lt/veikla/veiklos-sritys/kompensuojamieji-vaistai/Documents/SAMv960_RedNr_2.pdf
46. Halota W, Flisiak R, Boron-Kaczmarska A. Standardy leczenia wirusowych zapalen watroby typu C Rekomendacje Polskiej Grupy Ekspertów HCV - 2011. , http://www.choroby-zakazne.pl/uploads/REKOMENDACJE%20PGE-HCV%202011-1.pdf
47. Carta Alba a hepatitei C in Romania. , http://www.aluzii.ro/wp-content/uploads/2013/03/CARTA-ALBA-A-HEPATITEI-C-IN-ROMANIA.pdf
48. Scotish intercollegiate Guidelines Network. Management of hepatitis C: a national clinical guideline. , http://www.sign.ac.uk/pdf/sign133.pdf
49. Glasa J, Skladaný T, Holomáň J. Method Statement on Rational Therapy. , http://www.health.gov.sk/?metodicke-listy-racionalnej-farmakoterapie
50. Maticic M, Kastelic A. National guidelines for the management of hepatitis C virus infection in drug users in Slovenia. Zdrav Vestn 2009, 78:529-539.
51. Maticic M, Brinovec V, Lesnicar G, Vidmar L, Meglic-Volkar J. Hepatitis C v Sloveniji. ISIS 1999, 8:49-51.
52. Generalitat de Catalunya, Departament de Salut. Criteris de indicacio del tractament de les hepatitis viriques. , http://www20.gencat.cat/docs/canalsalut/Home%20Canal%20Salut/Professionals/Desenvolupament_professional/Grups_de_treball/Consells_assessors_sobre_lus_racional_dels_medicaments/Consell_assessor_sobre_el_tractament_farmacologic_de_les_hepatitis_viriques/documents/arxius/crit_indica.pdf
53. Rihtlijnbehandeling van chronischen hepatitis C virusinfectie. , http://www.mdl.nl/uploads/240/474/7019_krt_mdl_hepatitis_c_12.pdf
54. Croes E, van der Poel A. ImplemenatioevoorstelvooreenDoorbrakkproject opsporing en behandeling van hepatitis C in de verslavingszorg. , http://www.trimbos.nl/~/media/Themas/3_Preventie/Infectieziekten/Doorbraak%20Opsporing%20en%20behandeling%20HCV%20in%20verslavingszorg.ashx
55. Netherlands institute of mental health and addiction. Doorbraakproject hepatitis C in de verslavingszorg. , http://www.trimbos.nl/~/media/Themas/3_Preventie/Infectieziekten/Factsheet%20Doorbraak%20Hepatitis%20C.ashx
56. Department of health. Hepatitis strategy for England. , http://www.nhs.uk/hepatitisc/SiteCollectionDocuments/pdf/hepatitis-c-strategy-for-england.pdf
57. Department for health. Hepatitis action plan for England. , http://www.nhs.uk/hepatitisc/SiteCollectionDocuments/pdf/hepatitis-c-action-plan-for-england.pdf
58. National institute for health and care excellence. PH43 Hepatitis B and C - ways to promote and offer testing:guidance. , http://www.nice.org.uk/Search.do?x=0&y=0&searchText=hepatitis&newsearch=true&page=1#/search/?reload
59. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008, 33:126-133. 3800027, 18165889.
60. Grebely J, Raffa JD, Ali C, Krajden M, Kerr T, Fischer B, Tyndall MW. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hep 2009, 16:352-358.
61. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patient with rapid virological response: a meta-analysis. J Hepatol 2010, 52:25-31.
62. European Association for the study of the liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60:392-420. European Association for the study of the liver.
63. Lazarus JV, Sperle I, Maticic M, Wiessing L. A systematic review of hepatitis C virus treatment access in people who inject drugs in the European region and the availability of medicine to treat them. BMC Infectious Diseases 2014,
64. Maticic M, SelicKurincic T, Kastelic A, Poljak M, Lesnicar G, Meglic-Volkar J, Rajter M, Prah J, Baklan Z, Ciglaric M, Pancur M. A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia: high enrollement, adherence and sustained virological response [Abstract]. Suchtmed 2013, 15:245.
65. Hutchinson S, Goldberg D, Brown G, Rowan N, Dillon J, Taylor A, Ahmed S. Hepatitis C strategy in Scotland. Viral Hepatitis in Practice 2012, 4(2):1-4.
66. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, Castleen G, van Santen G, van der Berg CH, Coutinho RA, Prins M, Weeking CJ. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011, 23:23-31.
67. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138:123-135. 2813391, 19782085.
68. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once daily ribavirin. J Subst Abuse Treat 2010, 38:338-345.
69. Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, Marcellin P, Cacoub P. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J GastroenterolHepatol 2010, 22:1050-1057.
70. Aspinall E, Corson S, Doyle J, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis 2013, 57(Suppl 2):80-89.
71. European Association for the study of the liver EASL international consensus conference on Hepatitis C. Paris, 26-28, February 1999, consensus statement. J Hepatol 1999, 30:956-961. European Association for the study of the liver.
72. European Association for the study of the liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the study of the liver.
73. World Health Organisation. Global policy report on the prevention and control of viral hepatitis. , http://www.who.int/topics/hepatitis
74. Morris K. Tackling hepatitis C: a tale of two countries. Lancet 2011, 377:1227-1228.
75. Maasoumy B, Manns MP. Optimal treatment with boceprevir for chronic HCV infection. Liver Int 2013, 33(Suppl 1):14-22.
76. Hill A, Khool S, Fortunak J, Simmons B, Ford N. Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014,
77. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013, 57(Suppl 2):56-61.
78. Selin J, Hakkarainen P, Partanen A, Tammi T, Tigerstedt C. From political controversy to a technical problem? Fifteen years of opioid substitution treatment in Finland. Int J Drug Policy 2013, 24:66-72.